WAThealthcarenyseupdated 10:33:08 PM

Waters Corporation logoWaters Corporation

Waters Corporation (WAT) is a healthcare company operating in diagnostics & research. Valuation and momentum can move with trial outcomes, regulatory news, and reimbursement shifts. Use this profile to monitor momentum shifts, volatility regime, and valuation signals in one dashboard.

Price

$443.26

+0.07% today

Risk

Medium

22.0% vol · 30d

share this asset

Key facts, as of

As of September 29, 2026, Waters Corporation (WAT) trades at $443.26, up 53.1% over the past year. It is at the top of its 52-week range ($282.77 to $445.48). It sits 22.1% above its 200-day average of $362.91, the usual sign of a long-term uptrend. Its 30-day volatility is 22.0% annualized, which we rate medium risk. It has a trailing P/E of 112.5.

Cite: Portfolio Terminal, "Waters Corporation (WAT) stock analysis", 2026-09-29. https://portfolio-terminal.com/analyse/wat

01Market

Where it trades today

Market cap

$43.52B

Price / earnings

112.5x

Beta

1.19

swings more than the market

Dividend yield

none

Volume

625.3K

avg 782.0K

50-day average

$406.80

200-day average

$362.91

30-day trend

bullish

52-week rangenear the top of its year
low $282.77$443.26high $445.48

trading 99% of the way up its 52-week range

02Price

How the price has moved

30-day price+6.90%
30 days ago$414.63 → $443.26today
1-year performance+35.0%
$321$369$417OctNovDecJanFebMarAprMayJunJulAugSep
WAT · 52 weeks$328.39 → $443.26
03Decision

What to weigh before acting

decision support3 sources

What Matters Now

  • The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
  • WAT trades at 112.5x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
  • WAT carries a beta of 1.19, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
  • WAT is in a bullish short-term regime and only 0.5% below its 52-week high, so the question is whether fundamentals can keep pace with that stronger tape.

Portfolio Use Case

  • WAT is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
  • This name works better as a satellite or higher-conviction growth position because it can amplify market swings in both directions.
  • The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.

What Would Change the View

  • A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in WAT.
  • If the short-term trend rolls over while volume fades, the market may stop paying up for momentum before the fundamentals change.
  • There is little income cushion here, so total return depends mainly on price appreciation and execution staying on track.

Methodology

  • Price, market cap, beta, yield, and liquidity fields for WAT come from Yahoo Finance quote and summary data.
  • 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
  • Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
  • Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.

Sources

  • Yahoo Finance quote dataopen →

    Live quote, valuation, beta, yield, and volume fields used for WAT. Last refresh: Sep 29, 2026, 10:33 PM.

  • Portfolio Terminal methodologyopen →

    Explains how analytics, refresh cadence, and portfolio interpretation work across the product.

  • Peer set and coverage context

    Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.

Editorial note · Written by Portfolio Terminal Research. Template updated 3/24/2026, market data refreshed 9/29/2026, 10:33:08 PM. Built for research and portfolio monitoring, not personalized investment advice.
04About

What Waters Corporation does

profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life…

Employees

16,000

Industry

Diagnostics & Research

Headquarters

Milford, United States

05Analyst Consensus

What analysts expect

WAT carries a buy consensus from 24 analysts, with an average price target of $444.79 versus $443.26 today (+0.3%). Targets are estimates and can move quickly after earnings.

Consensus

Buy

Average target

$444.79

$349.00 to $515.00

Upside to target

+0.3%

Analysts covering

24

Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.

06Financial Strength

How the business is doing

WAT generated $4.64B in trailing revenue (113.4% year over year), with a 3.6% net margin, and -$142.07M of free cash flow, against $4.94B of net debt.

Revenue (TTM)

$4.64B

Net margin

3.6%

Revenue growth

113.4%

Free cash flow

-$142.07M

Gross margin

56.3%

Operating margin

9.4%

Return on equity

1.9%

Total cash

$539.00M

Total debt

$5.48B

Earnings growth

N/A

07Annual Financials

The numbers, year by year

annual financials4 years
Fiscal yearRevenueGross profitOperating incomeNet incomeEPSFree cash flow
2025$3.17B$1.88B$802.59M$642.63M$10.80$539.81M
2024$2.96B$1.76B$837.92M$637.83M$10.75$619.64M
2023$2.96B$1.76B$817.68M$642.23M$10.87$442.18M
2022$2.97B$1.72B$883.19M$707.75M$11.80$428.20M
Company filings via Yahoo Finance. Refreshed 9/29/2026.
08Next Earnings

When it reports next

Next report

Oct 30, 2026

EPS estimate

$4.00

Revenue estimate

$1.75B

Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.

09Sector

How it sits in healthcare

Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.

versus the sectorWAT vs average
metricWATsectorverdict
price / earnings112.5x22.0x↑ 411%
beta1.190.85more volatile
30-day volatility22.0%22%lower risk
10Peers

The companies it competes with

WAT beside the healthcare names it is usually measured against.

competitors4 companies
companypricemarket cap
Waters Corporation logoWAT$443.26$43.52B
UnitedHealth Group logoUNH$374.94$336.54BJohnson & Johnson logoJNJ$267.57$644.82BPfizer Inc. logoPFE$28.72$163.69B
Any row opens that company's own analysis.
11Technicals

What the chart is saying

Trading at its high for the year, with no resistance overhead.

uptrend
wat · daily
50-day 407200-day 363resistancesupport
3003507030RSI 14 · 69volS 411S 399443AprMayJunJulAugSep
Daily candles · WATLevels are zones where the price turned at least twice in the last year. Last close $443.26 on 2026-09-29.

RSI (14)

69

neutral zone

vs 50-day

+9.0%

avg $406.80

vs 200-day

+22.1%

avg $362.91

From 1-year high

−0.5%

high $445.48 · 2026-09-28

levels and the read24% annualized vol · 30d
support$411.41turned here 2×−7.2%
support$398.55turned here 2×−10.1%
  • Price is 9.0% above its 50-day average and 22.1% above its 200-day.
  • The 50-day crossed above the 200-day on 2026-07-01 (a “golden cross”).
  • RSI at 69 is neither stretched nor washed out.
  • Nothing above has stopped it this year; the nearest floor is $411.41 (-7.2%).

A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.

12Questions

Questions people ask about it

questions5 answered

Is WAT a good buy right now?

Waters Corporation trades at 112.5x earnings. This is above market average, reflecting growth expectations. Current risk level is Medium based on 22.0% volatility.

Does WAT pay dividends?

Waters Corporation does not currently pay a regular dividend. The company may be reinvesting profits for growth.

How volatile is WAT?

With 30-day annualized volatility of 22.0% and beta of 1.19, WAT is classified as Medium risk. Expect larger swings than the broader market during volatile periods.

What is the analyst price target for WAT?

The average analyst price target for Waters Corporation (WAT) is $444.79 based on 24 analyst estimates, about 0.3% above the current price of $443.26. The published range runs from $349.00 to $515.00.

How much revenue does WAT generate?

Waters Corporation reported $4.64B in trailing twelve-month revenue. Revenue growth is running at 113.4% year over year. Net margin sits at 3.6%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.

Compare WAT with anything

Five years side by side: what $10,000 became, how far each fell, whether they move together.

Waters Corporation logo